Verve Therapeutics, Inc.

Caroline Reiss

Kallanthottathil G Rajeev

Alexandra Chadwick

Christopher Cheng

Souvik Biswas

Padma Malyala

Lisa N Kasiewicz

Ellen Rohde

Provided herein are compositions and methods for preparation of 5' end region-modified mRNAs. In particular, the instant disclosure relates to novel mRNA 5′ end region motifs and sequence initiators therefore together with assays that are capable of measuring the aspects of the functionality of those motifs and sequence initiators. Further provided herein are compositions and methods of treating conditions related to coronary disease.

Compositions and methods for capping RNAS

Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.

Base editing of ANGPTL3 and methods of using same for treatment of disease

Base editing of PCSK9 and methods of using same for treatment of disease

Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease.

Compositions and methods for targeted RNA delivery

Growing community of inventors

Somerville, MA, United States of America

Caroline Reiss